2,749 reports of this reaction
2.7% of all EMPAGLIFLOZIN reports
#5 most reported adverse reaction
WEIGHT DECREASED is the #5 most commonly reported adverse reaction for EMPAGLIFLOZIN, manufactured by Boehringer Ingelheim Pharmaceuticals, Inc.. There are 2,749 FDA adverse event reports linking EMPAGLIFLOZIN to WEIGHT DECREASED. This represents approximately 2.7% of all 100,203 adverse event reports for this drug.
Patients taking EMPAGLIFLOZIN who experience weight decreased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
WEIGHT DECREASED is a less commonly reported adverse event for EMPAGLIFLOZIN, but still significant enough to appear in the safety profile.
In addition to weight decreased, the following adverse reactions have been reported for EMPAGLIFLOZIN:
The following drugs have also been linked to weight decreased in FDA adverse event reports:
WEIGHT DECREASED has been reported as an adverse event in 2,749 FDA reports for EMPAGLIFLOZIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
WEIGHT DECREASED accounts for approximately 2.7% of all adverse event reports for EMPAGLIFLOZIN, making it a notable side effect.
If you experience weight decreased while taking EMPAGLIFLOZIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.